Literature DB >> 23354771

Prevalence of upper gastrointestinal symptoms and their influence on nutritional state and performance status in patients with different primary tumors receiving palliative care.

Giacomo Bovio1, Maria Luisa Fonte, Paola Baiardi.   

Abstract

The aim of this study was to investigate the relationship between gastrointestinal symptoms, nutritional balance, and performance status in patients receiving palliative care for advanced cancers originating in different sites. We studied a total of 105 patients. Upper gastrointestinal symptoms, Eastern Cooperative Oncology Group Performance Status score (ECOG-PS), dietary intakes, anthropometric measures, and some serum proteins were determined. Unintentional weight loss, alterations in anthropometric measures, and highest number of symptoms were greater in patients with lung and stomach cancer. No differences were found in ECOG-PS according to cancer site. Patients with gastric or lung cancer have most evidence of protein-calorie malnutrition and a higher prevalence of upper gastrointestinal symptoms. The performance status is not affected by tumor site. Early nutritional support should be planned for all patients with cancer, especially for patients with gastric or lung cancer.

Entities:  

Keywords:  advanced cancer; malnutrition; nutritional status; palliative care; performance status; upper gastrointestinal symptoms

Mesh:

Substances:

Year:  2013        PMID: 23354771     DOI: 10.1177/1049909112474713

Source DB:  PubMed          Journal:  Am J Hosp Palliat Care        ISSN: 1049-9091            Impact factor:   2.500


  2 in total

1.  Serum adiponectin levels may be associated with the pathogenesis of hepatocellular carcinoma.

Authors:  Rong-Rong Song; Xiao-Lin Gu
Journal:  Tumour Biol       Date:  2014-12-11

2.  Cancer Appetite and Symptom Questionnaire (CASQ) for Brazilian Patients: Cross-Cultural Adaptation and Validation Study.

Authors:  Maria Claudia Bernardes Spexoto; Sergio Vicente Serrano; Vanessa Halliday; João Maroco; Juliana Alvares Duarte Bonini Campos
Journal:  PLoS One       Date:  2016-06-08       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.